Innovative cutting edge

approaches to controlling

immune mediated

diseases

Torudokimab

Torudokimab is a fully human, high affinity monoclonal antibody that neutralizes IL33 and is currently at the Phase 2 clinical development stage.

Zura Bio holds an exclusive license for the development and commercialization of Torudokimab

IL33 is a validated drug target in both chronic obstructive pulmonary disease (COPD) and asthma.

Drug well tolerated in Phase 1 and 2 trials conducted by Lilly and shows utility in diseases driven by epithelial inflammation.

IL33 pathway

Targeting IL33 In Epithelial Driven Diseases

IL33 Pathway

IL33 is a member of the IL1 cytokine family that is constitutively expressed in structural and lining cells including fibroblasts, endothelial, and epithelial cells of skin, gastrointestinal tract, and lungs

IL33 is released from the epithelium by disease exacerbating environmental factors and is an important amplifier of innate inflammation during exacerbations

Polymorphisms in IL33 and ST2 are associated with increased eosinophil production as well as respiratory diseases such as COPD and Severe Asthma.

IL33 inhibition clinically validated in Severe asthma, COPD, and subsets of other epithelial disorders

REFERENCES

IL33: Roles in Allergic Inflammation and Therapeutic Perspectives

Chan BCL, Lam CWK, Tam L-S and Wong CK (2019) Front. Immunol. 10:364.

doi: 10.3389/fimmu.2019.00364

Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation

Cohen, E., Scott, I., Majithiya, J. et al. Nat Commun 6, 8327 (2015).

https://doi.org/10.1038/ncomms9327

Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma

Wechsler ME, Ruddy MK, Pavord ID, Israel E, Rabe KF, Ford LB, Maspero JF, Abdulai RM, Hu CC, Martincova R, Jessel A, Nivens MC, Amin N, Weinreich DM, Yancopoulos GD, Goulaouic H. N Engl J Med. 2021 Oct 28;385(18):1656-1668.

doi: 10.1056/NEJMoa2024257